S
SOPHiA GENETICS
Democratizing data-driven medicine
Rolle, Switzerland (US HQ in Boston, MA)
500+
About SOPHiA GENETICS
Industry:
Genomic & Multimodal Data Analytics
Founded:
2011
Founders:
Jurgi Camblong, Pierre Hutter, Lars Steinmetz
Status:
Public (NASDAQ: SOPH)
Funding & Growth
Total Raised:
$249M + IPO
Stage:
Public (NASDAQ: SOPH)
Key Investors:
Balderton Capital
Endeavour Vision
Generation IM
✓ Pros
- • Established, at-scale platform (990+ institutions)
- • Public company (NASDAQ: SOPH)
- • Multimodal — genomics plus radiomics
- • Global footprint (75+ countries)
✗ Cons
- • Larger org (500-1,000) — less startup feel
- • Public-market pressure
- • Swiss/Boston HQ, not France-based
🧬 Bioinformatics Focus
SOPHiA GENETICS runs SOPHiA DDM, a cloud platform that analyzes genomic and imaging data to support precision medicine in oncology and rare disease.
The platform is used by 990+ healthcare institutions across 75+ countries and has analyzed millions of genomic profiles.
Founded in 2011 at EPFL in Lausanne, the company is now dual-headquartered in Switzerland and Boston and trades on NASDAQ (SOPH).